International Assets Investment Management LLC Has $7.21 Million Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

International Assets Investment Management LLC raised its stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 319.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 205,335 shares of the biotechnology company’s stock after purchasing an additional 156,353 shares during the period. International Assets Investment Management LLC’s holdings in Aldeyra Therapeutics were worth $7,210,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALDX. State Street Corp increased its stake in Aldeyra Therapeutics by 1,655.5% in the second quarter. State Street Corp now owns 3,041,866 shares of the biotechnology company’s stock valued at $25,521,000 after purchasing an additional 2,868,585 shares in the last quarter. BlackRock Inc. increased its stake in Aldeyra Therapeutics by 228.0% in the second quarter. BlackRock Inc. now owns 3,230,414 shares of the biotechnology company’s stock valued at $27,103,000 after purchasing an additional 2,245,432 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Aldeyra Therapeutics by 1,254.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,391,018 shares of the biotechnology company’s stock valued at $6,183,000 after purchasing an additional 1,288,353 shares in the last quarter. Knoll Capital Management LLC increased its stake in Aldeyra Therapeutics by 45.9% in the second quarter. Knoll Capital Management LLC now owns 3,015,668 shares of the biotechnology company’s stock valued at $25,301,000 after purchasing an additional 948,508 shares in the last quarter. Finally, UBS Group AG increased its stake in Aldeyra Therapeutics by 371.2% in the first quarter. UBS Group AG now owns 960,393 shares of the biotechnology company’s stock valued at $4,269,000 after purchasing an additional 756,593 shares in the last quarter. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Price Performance

NASDAQ:ALDX opened at $4.25 on Monday. The firm has a 50-day moving average of $3.51 and a 200-day moving average of $3.31. The company has a market cap of $250.31 million, a PE ratio of -6.64 and a beta of 1.51. Aldeyra Therapeutics, Inc has a one year low of $1.42 and a one year high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.13. On average, equities research analysts expect that Aldeyra Therapeutics, Inc will post -0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd. Oppenheimer raised shares of Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research report on Wednesday, April 3rd. Finally, StockNews.com raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 29th.

Insiders Place Their Bets

In other news, major shareholder Perceptive Advisors Llc acquired 8,374 shares of Aldeyra Therapeutics stock in a transaction on Monday, April 1st. The stock was acquired at an average cost of $3.25 per share, with a total value of $27,215.50. Following the transaction, the insider now owns 8,601,960 shares of the company’s stock, valued at approximately $27,956,370. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, major shareholder Perceptive Advisors Llc acquired 8,374 shares of Aldeyra Therapeutics stock in a transaction on Monday, April 1st. The stock was acquired at an average cost of $3.25 per share, with a total value of $27,215.50. Following the transaction, the insider now owns 8,601,960 shares of the company’s stock, valued at approximately $27,956,370. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Todd C. Brady sold 97,914 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the sale, the chief executive officer now directly owns 1,556,622 shares of the company’s stock, valued at $5,090,153.94. The disclosure for this sale can be found here. In the last ninety days, insiders bought 355,933 shares of company stock valued at $1,473,245. Corporate insiders own 7.30% of the company’s stock.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.